Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2025—Biocartis’ Idylla CDx MSI test, developed in partnership with Bristol Myers Squibb, has received FDA premarket approval. The test aids in identifying eligible microsatellite instability-high colorectal cancer patients who may benefit from treatment with Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), as established in the CheckMate 8HW trial.
October 2025—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software throughout the Asia-Pacific region. The software is designed to help troubleshoot quality control errors and increase confidence in patient testing results. It offers on-demand access to peer reporting and quality control data and provides data visualization and report generation for compliance management. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.
October 2025—Randox Laboratories plans to expand its facility in Jefferson County, W. Va., from a 48-person sales and distribution operation to a full-scale production laboratory. The company says the expansion will further increase its annual production of 4.1 billion tests and significantly enhance its capacity to serve customers worldwide, from hospitals, laboratories, and coroners’ offices to food safety testing facilities. The project will create opportunities for local suppliers and service providers. Once complete, the upgraded facility in Kearneysville will produce next-generation diagnostic products and equipment.
October 2025—Scopio Labs received FDA clearance to include decision support system features for its X100 and X100HT platforms and Peripheral Blood Smear Application. The upgraded solution provides AI-driven analysis and grading for 23 distinct RBC morphology parameters and for the presence of platelet clumps across the clinically relevant areas of the sample, from the monolayer to the feathered edge.
October 2025—Knowledge of laboratory tests that most effectively work up a patient presenting with bleeding or clotting manifestations is crucial to develop a sound and timely action plan for the benefit of the patient. It is important for medical professionals to know which tests best evaluate the causes of hemostasis disorders and what common clinical scenarios can significantly interfere with accurate test results, such as the impact of anticoagulant agents on routine and special coagulation assay results.
October 2025—MeMed has completed its multiyear development of MeMed BV Flex, a next-generation test designed to expand the reach of MeMed BV into decentralized, CLIA-waived settings. The test enables differentiation between bacterial and viral infections in 15 minutes using capillary blood from a finger prick.
October 2025—The Food and Drug Administration has categorized Roche’s Ionify 25-Hydroxy Vitamin D total assay as moderate complexity under the Clinical Laboratory Improvement Amendments of 1988. Roche reported that this is the first time a mass-spectrometry-based test has achieved this designation.
October 2025—Eppendorf has launched the Eppendorf Research 3 Neo mechanical pipette. Users can choose between two volume settings and speeds. The pipette can be adjusted for different liquid types, tip geometries, and reverse pipetting and a volume lock feature prevents unintentional volume changes. The use of ColorTag marking rings provides color-coded identification.
October 2025—The Food and Drug Administration has granted breakthrough device designation for Quest Diagnostic’s Haystack MRD circulating tumor DNA test. The test is used for identifying minimal residual disease in patients with stage two colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.
October 2025—The FDA has cleared Hardy Diagnostics’ NG-Test CTX-M Multi, an in vitro diagnostic immunoassay for the qualitative detection of CTX-M enzymes (groups 1, 2, 8, 9, and 25) from pure colonies of Enterobacterales suspected of extended-spectrum beta-lactamase production. These enzymes confer resistance to many beta-lactam antibiotics, making infections more difficult to treat. The test delivers results in 15 minutes.
